Name: Recombinant Anti-B Cell Lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (scIgG)
SKU: SCIGG-016
Rating: 5 (1 reviews)

Recombinant Anti-B cell lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-B cell lymphoma BCL1 Idiotype and anti-CD3 IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can block cell adhesion. It is designed for the research of B cell lymphoma therapy.

Datasheet INQUIRY

Specifications

Targets

B Cell Lymphoma BCL1 Idiotype & CD3

Type

Single chain IgGs

Species Reactivity

Mouse

Application

FuncS; Promising therapeutic agent

Related Disease

B cell lymphoma

Host Animal 1

Rat

Host Animal 2

Mouse

Targets

Target 1

B Cell Lymphoma BCL1 Idiotype

Alternative Names

B cell lymphoma BCL1 Idiotype; B cell lymphoma; BCL1; Idiotype; Id; 31D1; 32D1

Target 2

CD3

Gene ID

12501

UniProt ID

P24161

Alternative Names

CD3; CD3E; CD3e molecule; Cluster of differentiation 3; CD3e molecule, epsilon (CD3-TCR complex); T3E; TCRE; IMD18; T-cell surface glycoprotein CD3 epsilon chain; CD3-epsilon; T-cell surface antigen T3/Leu-4 epsilon chain; CD3e antigen, epsilon polypeptide (TiT3 complex); T-cell antigen receptor complex, epsilon subunit of T3; AI504783

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Related products of "B Cell Lymphoma BCL1 Idiotype & CD3"

See other bsAb targets related to "CD3"

See other bsAb targets related to "B Cell Lymphoma BCL1 Idiotype"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-B Cell Lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (scIgG) (SCIGG-016). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-B Cell Lymphoma BCL1 Idiotype x Anti-CD3 Bispecific Antibody (scIgG) (CAT#: SCIGG-016)

Specifications

Targets

Customer Reviews and Q&As